OncoC4 Advances PD-1/VEGF Bispecific Antibody AI-081 to Phase 2 Trial Following Promising Early Efficacy Data
核心洞察
OncoC4 (搜索) has dosed the first patient in the Phase 2 portion of the BIPAVE-001 trial evaluating AI-081, a potentially best-in-class PD-1 (搜索)/VEGF (搜索) bispecific antibody for advanced solid tumors (搜索).
The Phase 1 dose escalation demonstrated excellent safety, favorable pharmacokinetics, and objective anti-tumor response at the lowest tested dose of 1 mg/kg.
AI-081 combines proprietary anti-PD1 and anti-VEGF (搜索) antibodies in a head-and-tail bispecific configuration designed for enhanced dual-targeted immune responses.
OncoC4 (搜索), Inc. has initiated the Phase 2 portion of its BIPAVE-001 clinical trial, dosing the first patient with AI-081, a potentially best-in-class PD-1 (搜索) and VEGF (搜索) bispecific antibody for advanced solid tumors (搜索). The milestone follows encouraging safety and efficacy data from the Phase 1 dose escalation portion of the study.
Promising Early Clinical Results
The Phase 1 dose escalation demonstrated excellent safety profiles and favorable pharmacokinetics across all tested doses. Notably, objective anti-tumor responses were observed at the lowest dose tested of 1 mg/kg, which represents a lower effective dose compared to other VEGF (搜索) and PD-1 (搜索)/PD-L1 bispecific therapies currently in clinical development.
"We are encouraged by the excellent safety, favorable pharmacokinetics and promising efficacy seen across the initial dose escalation of AI-081," said Pan Zheng, MD, PhD, Co-Founder and Chief Medical Officer of OncoC4 (搜索). "Importantly, objective anti-tumor response was observed at the lowest dose tested, which is lower than other VEGF (搜索) and PD-1 (搜索)/PD-L1 bispecific therapies in clinical development."
Trial Design and Patient Population
The BIPAVE-001 Phase 1/2 trial (NCT06635785) evaluates AI-081 through two integrated components. Part A represents the ongoing first-in-human Phase 1 dose escalation and dose expansion study in patients with advanced solid tumors (搜索). Part B, the newly initiated Phase 2 portion, includes dose optimization trials comparing AI-081's safety and clinical activities as both monotherapy and in combination with standard of care treatments in selected indications.
The study operates across 11 clinical sites in the United States, with active patient enrollment ongoing. The Chinese regulatory agency has also cleared the study for potential expansion.
Innovative Bispecific Design
AI-081 combines two proprietary, clinical-stage high-affinity antibodies: anti-PD1 (AI-025) and anti-VEGF (搜索) (AI-011). The drug employs a tested and clinically proven head-and-tail bispecific configuration designed for strong cooperative interactions between the two therapeutic pathways.
The bispecific antibody incorporates additional Fc silencing mutations to preserve immune effector cells. In preclinical studies supporting the investigational new drug application, AI-081 demonstrated higher affinity for both targets, more effective cooperation between pathways, and enhanced in vivo activities compared to other drug candidates in the same therapeutic class.
Focus on Non-Small Cell Lung Cancer
The Phase 2 trial will initially focus on dose optimization in non-small cell lung cancer (搜索) (NSCLC (搜索)), representing a significant unmet medical need in oncology. Dr. Zheng noted that the early clinical signals are "consistent with AI-081's best-in-class potential demonstrated by data from multiple preclinical cancer models."
The company anticipates that the current Phase 1/2 trial design could enable two or more pivotal studies, potentially accelerating the path to regulatory approval for this novel bispecific antibody approach to cancer treatment.